The FDA issued a Form 483 with nine observations to generics manufacturer Aurolife Pharma following a six-week inspection of the company’s manufacturing facility in Dayton, N.J., from Oct. 25 through Dec. 7, in which the company attributed some of its data deficiencies to a cyberattack.
Source: Drug Industry Daily